Related references
Note: Only part of the references are listed.Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study
Jeong-Hoon Lee et al.
CLINICAL INFECTIOUS DISEASES (2021)
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy
Michel Bazinet et al.
GASTROENTEROLOGY (2020)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection
Heiner Wedemeyer et al.
JOURNAL OF HEPATOLOGY (2019)
Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study
Di Wu et al.
HEPATOLOGY INTERNATIONAL (2019)
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Abdulraheem Yacoub et al.
BLOOD (2019)
Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection
Yuchen Xia et al.
GASTROENTEROLOGY (2019)
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection
Man Fung Yuen et al.
GASTROENTEROLOGY (2019)
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
Lucia Masarova et al.
LANCET HAEMATOLOGY (2017)
Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis
Young Eun Chon et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
Rong Fan et al.
GUT (2016)
Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection
Richard A. Colvin et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Reduced Toll-like receptor 9 expression on peripheral CD14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy
Yi-Wen Huang et al.
ANTIVIRAL THERAPY (2014)
Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B-A Nationwide Cohort Study
Chun-Ying Wu et al.
GASTROENTEROLOGY (2014)
Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: A randomized trial
Jun Cheng et al.
JOURNAL OF CLINICAL VIROLOGY (2014)
Biphasic pattern of depression and its predictors during pegylated interferon-based therapy in chronic hepatitis B and C patients
Yi-Wen Huang et al.
ANTIVIRAL THERAPY (2013)
Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy
Yi-Wen Huang et al.
ANTIVIRAL THERAPY (2013)
Shorter Durations and Lower Doses of Peginterferon alfa-2a Are Associated with Inferior Hepatitis B e Antigen Seroconversion Rates in Hepatitis B Virus Genotypes B or C
Y. -F. Liaw et al.
HEPATOLOGY (2011)
Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B
Yi-Wen Huang et al.
ANTIVIRAL THERAPY (2010)
Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3
David R. Nelson et al.
GASTROENTEROLOGY (2010)
Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1
Stefan Zeuzem et al.
GASTROENTEROLOGY (2010)
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2008)
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
GKK Lau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Peginterferon α-2a (40 kDa):: an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
WGE Cooksley et al.
JOURNAL OF VIRAL HEPATITIS (2003)
Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
JH Kao et al.
GASTROENTEROLOGY (2000)
Share Paper
